AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04109755
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
Trial: NCT01900327
Drug: Gemcitabine neoadjuvant
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
Trial: NCT04876287
Drug: Radioiodine
RxNorm normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cancer therapy
Trial: NCT01900327
Drug: Gemcitabine adjuvant
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
Trial: NCT00531024
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
Trial: NCT00531024
Drug: Sodium Chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
Trial: NCT03784404
Drug: Intracytoplasmic sperm injection
RxNorm normalized name: herring sperm DNA
DrugBank: Herring (DB10617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance.
Trial: NCT02113878
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin is a chemotherapy drug
Trial: NCT02588170
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Trial: NCT01028339
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol
Trial: NCT01382446
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
Trial: NCT01550510
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 350mg/m2 once a week every 3 weeks
Trial: NCT00455364
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03008083
Drug: 3 months DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
Trial: NCT03008083
Drug: 12 months DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
Trial: NCT04336982
Drug: CC-90009
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT04336982
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet
Trial: NCT04336982
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injection
Trial: NCT04336982
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet
Trial: NCT04164615
Drug: GB221
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GB221:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.
Trial: NCT03542344
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single rising oral dose
Trial: NCT01263041
Drug: Glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
Trial: NCT04264637
Drug: Azelastine hydrochloride (BAYR9258)
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration.
Trial: NCT03795519
Drug: [14C]-olinciguat
DrugBank: Olinciguat (DB15238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT00088699
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00294736
Drug: Tarceva
RxNorm normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Escalation: 150-350+ mg/day
Trial: NCT00431379
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02344472
Drug: pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HER2 targeted Therapy
Trial: NCT02344472
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HER2 targeted Therapy
Trial: NCT02344472
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy
Trial: NCT02344472
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT02344472
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT02344472
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: endocrine therapy
Trial: NCT02344472
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: endocrine therapy
Trial: NCT02344472
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: endocrine therapy
Trial: NCT02344472
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: endocrine therapy
Trial: NCT02344472
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CDK 4/6 inhibitor
Trial: NCT02344472
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: chemotherapy
Trial: NCT02344472
Drug: eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: chemotherapy
Trial: NCT02344472
Drug: leuprorelin
RxNorm normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: endocrine therapy
Trial: NCT02344472
Drug: goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: endocrine therapy
Trial: NCT00467493
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01557244
Drug: Fesoterodine PR 4 mg
RxNorm normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg tablet once daily for 24 weeks
Trial: NCT01557244
Drug: Fesoterodine PR 8 mg
RxNorm normalized name: fesoterodine fumarate 8 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
Trial: NCT01557244
Drug: Fesoterodine PR 8 mg
RxNorm normalized name: fesoterodine fumarate 8 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
Trial: NCT01557244
Drug: Oxybutynin
RxNorm normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
Trial: NCT01557244
Drug: Fesoterodine PR
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
Trial: NCT01557244
Drug: Fesoterodine BIC 2 mg
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
Trial: NCT01557244
Drug: Fesoterodine BIC 4 mg
RxNorm normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
Trial: NCT00800345
Drug: Oral Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
Trial: NCT00800345
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
Trial: NCT00944645
Drug: niacin (+) laropiprant (Source 1)
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
Trial: NCT00944645
Drug: Comparator: niacin (+) laropiprant (Source 2)
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
Trial: NCT00231595
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00073554
Drug: Alfimeprase
RxNorm normalized name: Alfimeprase
DrugBank: Alfimeprase (DB04919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01263041
Drug: l-arginine
RxNorm normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
Trial: NCT01334567
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
Trial: NCT00945880
Drug: clemizole hydrochloride
RxNorm normalized name: Clemizole
DrugBank: Clemizole (DB15932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
Trial: NCT04179084
Drug: fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg qd, 2weeks on, 1week off
Trial: NCT04179084
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg q3w
Trial: NCT03436732
Drug: LMB-100
RxNorm normalized name: LMB-100
DrugBank: LMB-100 (DB18591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles
Trial: NCT03436732
Drug: SEL-110
RxNorm normalized name: SEL 037
DrugBank: Pegadricase (DB15129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered on day 1 of each cycle for up to 4 cycles
Trial: NCT02278250
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT00415103
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
Trial: NCT00415103
Drug: Palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
Trial: NCT00415103
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
Trial: NCT02956486
Drug: Elenbecestat
RxNorm normalized name: Elenbecestat
DrugBank: Elenbecestat (DB15391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT00434811
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
Trial: NCT00434811
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
Trial: NCT00006337
Drug: KW-6002
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03295942
Drug: OMP-336B11
RxNorm normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
Trial: NCT00267488
Drug: topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02093520
Drug: Epidural Steroid Injection
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of epidural steroids into the lumbar spine
Trial: NCT01149460
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test 1000 mg Tablet
Trial: NCT01149460
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference Listed Valacyclovir 1000 mg Tablet
Trial: NCT00775151
Drug: amlodipine 10 mg tablet
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02674763
Drug: IMGN779
RxNorm normalized name: IMGN779
DrugBank: IMGN779 (DB17336)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00913367
Drug: glimepiride + insulin glargine (Amaryl + Lantus)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Amaryl® 4 mg at breakfast + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast
Trial: NCT00913367
Drug: glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast
Trial: NCT00433186
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate 3000 mg each day
Trial: NCT01037608
Drug: Sativex(Registered Trademark)
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01037608
Drug: THC
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01520441
Drug: BOTOX
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
Trial: NCT03193138
Drug: Hormonal therapies: G03, H01C and L02 in the ATC classification
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
Trial: NCT01145183
Drug: Doxazosin
RxNorm normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
Trial: NCT02049307
Drug: Losartan 100mg daily
RxNorm normalized name: losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05309564
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Single intervention
Trial: NCT04210310
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day
Trial: NCT00726479
Drug: BIBW 2948 BS
RxNorm normalized name: BS-001
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
Trial: NCT00982072
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
Trial: NCT03384966
Drug: Selatogrel
RxNorm normalized name: Selatogrel
DrugBank: Selatogrel (DB15163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.
Trial: NCT03384966
Drug: Selatogrel
RxNorm normalized name: Selatogrel
DrugBank: Selatogrel (DB15163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.